Correlation Between Circulating Resistin and Vascular Inflammation Measured by 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) (18FDG-PET)

This study has been completed.
Sponsor:
Information provided by:
Korea University
ClinicalTrials.gov Identifier:
NCT01150019
First received: June 9, 2010
Last updated: July 7, 2010
Last verified: April 2010

June 9, 2010
July 7, 2010
April 2010
June 2010   (final data collection date for primary outcome measure)
Vascular inflammation in carotid arterial wall represented as the target-to-background ratio (TBR) using FDG-PET [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Vascular inflammation in carotid arterial wall, represented as the target-to-background ratio (TBR), using FDG-PET [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01150019 on ClinicalTrials.gov Archive Site
  • Circulating serum adiponectin levels [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • carotid intima-media thickness levels measured using ultrasonography [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Circulating serum resistin levels [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Correlation Between Circulating Resistin and Vascular Inflammation Measured by 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) (18FDG-PET)
Correlation Between Circulating Resistin and Vascular Inflammation Measured by 18FDG-PET in Obese Person

Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis.Resistin was shown to induce vascular endothelial dysfunction and vascular smooth muscle cell proliferation.

18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.Therefore, the purpose of the study is to demonstrate the correlation between circulating resistin and vascular inflammation detected by 18FDG-PET in obese persons.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples Without DNA
Description:

Plasma, whole blood, serum

Non-Probability Sample

Healthy participats who underwent a medical health check in the health promotion center in Korea Guro University

Atherosclerosis
Other: Cross sectional study
This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
  • Obese Group
    Intervention: Other: Cross sectional study
  • Non Obese Group
    Intervention: Other: Cross sectional study
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
120
June 2010
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy volunteers for visiting routine medical check in our clinic

Exclusion Criteria:

  • History of cardiovascular disease (myocardial infarction, unstable angina,stroke, or cardiovascular revascularization)
  • Diabetes
  • Hypertension
  • Malignancy
  • Severe renal or hepatic disease
  • Subjects taking medications that might affect inflammation such as non-steroidal anti-inflammatory drugs (NSAIDs) and statin
Both
20 Years to 80 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01150019
PET_Resistin
Yes
Kyung Mook Choi, Korea University
Korea University
Not Provided
Principal Investigator: Kyung Mook Choi, MD.PhD Korea University
Korea University
April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP